This study is being conducted to better understand the natural course of GM1 gangliosidosis, GM2 gangliosidoses and Gaucher disease Type 2 (GD2). Information is planned to be gathered on at least 180 patients with GM1 gangliosidosis, GM2 gangliosidoses, and Gaucher Disease type 2. Retrospective data collection is planned for at least 150 deceased patients (Group A). Group B is for patients alive at the time of enrollment. In Group B it is planned to prospectively collect more comprehensive data from at least 30 patients. The purpose of this study is to collect relevant information for a adequate design of a potential subsequent research program in these diseases. In this study no therapy is being offered.
Study Type
OBSERVATIONAL
Enrollment
226
Ann & Robert H. Lurie Children's Hospital of Chicago
Chicago, Illinois, United States
Mayo Clinic - Rochester
Rochester, Minnesota, United States
Lysosomal and Rare Disorders Research and Treatment Center
Fairfax, Virginia, United States
UCL Cliniques Universitaires Saint-Luc
Brussels, Belgium
Hospital de Clínicas de Porto Alegre - HCPA
Porto Alegre, Brazil
AP-HP - Hôpitaux Universitaires Est Parisien
Paris, France
SphinCS GmbH
Höchheim, Germany
Azienda Ospedaliero Universitaria Meyer
Florence, Italy
Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta
Milan, Italy
Centro Hospitalar Universitario Lisboa Norte, EPE
Lisbon, Portugal
...and 7 more locations
Survival of pediatric patients with early onset of GM1 gangliosidosis, GM2 gangliosidoses, and Gaucher Disease type 2
Time frame: 2.5 years
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.